相关实验视频

Updated: May 20, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

新辅助性内分泌疗法与新辅助性化疗病理完整反应后的生存结果:一项回顾性国家数据库研究

Tori C Nierenberg¹, Samantha M Thomas^2,3, Ian Halliday¹

¹Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA.

Breast cancer research and treatment

|May 11, 2025

概括

对于雌激素受体阳性乳腺癌患者实现病理完整反应 (pCR),无论他们接受新辅助化疗 (NAC) 还是新辅助内分泌疗法 (NET),生存结果都是相似的. 这表明pCR具有相似的预后值,无论使用哪种疗法.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
临床结果临床结果

背景情况:

新辅助疗法对于治疗乳腺癌至关重要,病理完整反应 (pCR) 可以预测长期结果.
雌激素受体阳性 (ER+) 乳腺癌患者可以接受新辅助化疗 (NAC) 或新辅助内分泌疗法 (NET).

研究的目的:

为了比较非转移性ER+/HER2-乳腺癌患者的整体存活率 (OS),这些患者在接受NAC或NET后实现了pCR.

主要方法:

从国家癌症数据库 (2010-2021) 选择了一组3313名ER+/HER2-阶段I-III乳腺癌患者,这些患者获得了PCR后新辅助疗法.
总生存期 (OS) 估计使用卡普兰-梅尔分析和日志等级测试.
考克斯比例危险模型被用来评估NAC与NET和OS之间的关联,调整为共变量.

主要成果:

与接受NET治疗的患者相比,接受NAC治疗的患者更年轻,更有可能拥有私人保险和更大,更高等级的瘤.
尽管有人口和疾病特征的差异,但在未调整和调整的分析中,NAC和NET组之间总生存率 (OS) 没有显著差异.
五年后的运行概率为NAC的93.5%,NET的91.6% (p=0.08).

结论:

在ER+/HER2-早期乳腺癌患者的病理完整反应 (pCR) 与相似的整体生存 (OS) 结果有关,无论是否使用新辅助化疗 (NAC) 或新辅助内分泌疗法 (NET).
在不同类型的新辅助全身疗法中,pCR显示出一致的预后价值.

关键词:

乳腺癌是什么? 乳腺癌是什么化疗化疗是一种化学疗法.内分泌疗法是一种内分泌疗法.雌激素阳性乳腺癌是什么新辅助疗法是一种新辅助疗法.病理学完整的反应反应.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...